Analysts at Morgan Stanley raised the price target of Alexion Pharmaceuticals (NASDAQ: ALXN) to $121.00 on Tuesday. This is up from the earlier $120.00. The research firm further announces the rating of “equal weight” to NASDAQ: ALXN stocks.

Wall Street Analysts Rates NASDAQ: ALXN Stocks At “Buy”

Several Wall Street analysts have submitted their reports on the NASDAQ: ALXN stocks. ValuEngine upgraded the rating from “sell” to “hold” on September 17. TheStreet ranked it “c”, which is down from “b-” on July 30. Wedbush maintained the rating of “outperform” and posted the target price as $156.00 on NASDAQ: ALXN stocks on October 6. Oppenheimer reinstated a “hold” rating for NASDAQ: ALXN). William Blair did the same and put a “hold” rating on ALXN stocks.

Several Wall Street analysts covering NASDAQ: ALXN reported a “Buy” rating consensus on Alexion Pharmaceuticals this quarter. Along with this, the company also shares a consensus on the average target price of $141.81.

NASDAQ: ALXN Quarterly Earnings Estimate

The quarterly earnings for the previous fiscal quarter were released by the company on July 30. The earnings stood at $3.11 EPS for that quarter beating to the general consensus of $2.23 proposed by a consensus of analysts. The company’s return on equity also stood at 22.57% along with the net margin of 15.28%. The expected income for the firm was marked at $1.27 billion but it topped the estimate by making a revenue of $1.44 billion for that quarter.

NASDAQ: ALXN, a biopharmaceutical company has also been a recent attraction for many hedge funds and institutional investors.